Liver allografts matched for HLA. especially HLA-DR, have lower survival rates, not only in cyclosporine-treated patients (1.2) but also in patients on FK506 immunosuppression (3), Since H LA mismatching contributes to liver allograft rejection. we have proposed a dualistic role of HLA in liver transplanta-tion (1), HLA compatibility will reduce rejection but may augment other cellular immune mechanisms of liver allograft injury. especially those mediated by major histocompatibility complex-restricted lymphocytes, These mechanisms could be related to immune responses to viral infections and underlying autoimmune disease.
Cytomegalo\'irus hepatitis in liver transplant recipients has offered an opponunitv to im'estigate the dualistic role of HLA. C'.IV -specitic immune mechanisms are believed to he the primary mediators of liver allograft injury during CMV infection (-/). Several in vitro studies have demonstrated MHC-restricted lymphocyte responsiveness to CMV (5) (6) (7) (8) (9) (10) (11) . According to the MHC restriction concept, CMV antigen presentation by "self' HLA antigens will augment CMV -specific cellular immunity and cell-mediated injury. HLA matching of CMV -infected transplants patients will permit CMV antigen presentation by "self' HLA antigens. and this would promote T cell mediated effector mechanisms of allograft damage, In this report we present evidence that an HLA-DR compatibility is associated with more CMV hepatitis in liver transplant patients.
A significant complication of CMV infection is chronic rejection. Higher frequencies of graft coronarY arterv disease have been reported for c~n' . infected heart ~ranspiant recipients 112.13). In lung transplant patients. CMV infection is associated with bronchiolitis obliterans due to chronic rejection (14. 15) . In vitro proliferation assays have demonstrated a persistence of primed CMV -specific lymphocytes in hronchoalveolar lavages several months after symptomatic CMV infection, and this is associated with a high incidence of subsequent bronchiolitis obliterans (16) . Kidney transplant patients with CMV infection experience more rejection. and no differences have been noted in survivals of HLA-matched and mismatched kidney transplants (17. 18), Moreover. a higher incidence of CMV infection has been reported for patients with HLA-DRmatched kidney transplants ( 18, 19) . This suggests that CMV infection can override the beneticial effect of HLA matching on kidney transplant outcome.
In liver transplant patients. CMV infection is associated with the development of the vanishing bile duct syndrome, a manifestation of chronic rejection (20) . The incidence of vanishing bile duct syndrome appears to be higher for liver transplants from donors with HLA-DR matches (2). The studies described in this report show an association between chronic rejection and CMV hepatitis and also that HLA-DR matching accelerates the development of chronic rejection in liver transplant recipients. Dwgnosis of CMV hepatitis. This study focused on CMV hepatitis rather than CMV infection of liver transplant patients. The diagnosis of CMV hepatitis was based on ty-pical inclusion bodies or direct immunoperoxidase detection of CMV early antigen in a liver specimen obtained by (percutaneous) liver biopsy.
Diagnosis of chronic rejection. Histological criteria for chronic rejection are described elsewhere (22) and include lymphocytic bile duct damage in 50% or more of the portal triads. with evidence of bile duct loss and hepatocanalicular cholestasis.
Statistical anolvsis. Associations between HLA matching and CMV hepatitis and chronic rejection were assessed by Chl·square analysis. Odds ratios were calculated for the estimation of the relative risks. The \1ann Whitney 1..' nonparametric test· was used to analyze differences in the time of onset of chronic rejection between groups.
RESULTS
CMV hepatitis developed in 25 of 355 liver transplant patients 17";: I: the median time of diag-nosis was 33.5 days after transplantation (range: 13-278 days). The incidence of CMV hepatItis was significantly higher for HLA·DR-compatible liver transplants (Table 1) , Seventeen of the 25 CMV hepatitis patients 168':0) shared at least one HLA-DR antigen with the donor (Table 11 . In contrast. HLA-DR sharing was found in 123 of 330 patients 135':0) without CMV hepatitis I P=O.OOS). An HLA-DR match increased the relative risk of CMV HLA by a factor of 3.6. There seemed no preferential sharing of any particular HLA-DR antigen in the CMV hepatitis group. Also. the incidence of other symptomatic C~lV infections appeared unaffected by HLA-DR sharing. There were no differences between DR matched and unmatched hepatitis patients in terms of severity of liver dysfunction and responsiveness to gancic10vir therapy.
No significant associations were found between CMV hepatitis and donor-recipient sharing of HLA-A. HLA-B, and HLA-DQ antigens (Table 1) , In this group of FKS06-treated patients, a similar incidence of CMV hepatitis was seen in patients who received OKT3 (4/57 or 7%) and those without OKT3 treatment (21/298 or 7%).
Pretransplant CMV serological status was known for 262 HLA-DR-typed donor-recipient pairs ( Table 2) . Thirty-nine of the CMV -seronegative patients received CMV -seropositive grafts and 11 patients (28%) developed CMV hepatitis. In this group, the incidence of CMV hepatitis was about three times higher in livers with a shared HLA-DR antigen than in HLA-DR unmatched grafts (44% vs. 14%) (P=0.07). Of the other 36 seronegative recipients. only 3 (8%) who received livers from seronegative donors developed CMV hepatitis. Only one had HLA-DR sharing.
CMV hepatitis was observed in 1~ (5<;0) of 187 pretransplant seropositive patients. and 8 of these cases involved an HLA-DR match. Table 2 shows that in this group the frequency of hepatitis due to secondary CMV infection was 12% in HLA-DR-matched livers but only 2% in the HLA-DR-unmatchecj liver transplants (P=0.006)' These data suggest that HLA-DR sharing between recipient and donor increases the risk for both primary and secondary C:v1V hepatitis after liver transplantation.
During a follow-up of between 10 and 24 months after transplantation. 29 patients 18%) developed chronic rejection. The incidence of chronic rejection was four-fold higher in the CMV hepatitis group (24 C ;,) In the overall group of liver transplant patients. we did not find significant differences in the incidence of chronic rejection of liver transplants matched or mismatched for HLA-A.B,DR or DQ (Table 3) . However, HLA-DR sharing was associated with an earlier onset of chronic rejection in patients irrespective of CMV hepatitis status (Fig. 1) . The median onset of chronic rejection was 130 days (range: 35-284 days) for livers with an HLA-DR match and 356 days (range: 43-660 days) for HLA-DR-unmatched livers (P<O.Ol). Thus. HLA-DR matching appears to accelerate the development of chronic rejection after liver transplantation.
DISCliSSIO~
These observations suggest that HLA-DR sharing between donor and recipient promotes the development of CMV hepatitis in liver transplant patients. They are consistent with the concept of a dualistic role of HLA that predicts that HLA compatibility decreases graft rejection but may augment other cellular immune mechanisms of transplant injury. especially those mediated by MHC-restricted lymphocytes (1) . CMV disase appears to be mediated by cellular immune reactivity (4) , and several in"vitro studies have demonstrated HLA restricted lymphocyte reactivity toward CMV (5-11). The present data suggest that HLA-DR antigen sharing between donor and recipient leads to higher incidence of CMV hepatitis in liver transplant patients. No association of CMV hepatitis with HLA-A, HLA-B. and HLA-DQ sharing was observed. The incidence of CMV hepatitis was lower in this group of FK506-treated patients (7%) than that reported from our center in cyclosporine-treated liver transplant recipients (12%) (25) . Similarly, the incidence and severity of enteric CMV infection was less in FK506-treated than in cyclosporinetreated patients (26) .
In cyclosporine-treated patients OKT3 therapy is associated with a higher incidence of CMV infection (23) . Whereas patients on FK506 require less 0 KT3 therapy (2 I ) . it also appears that in FK506-treated patients. OKT3 does not promote CMV enteritis (26)-or. as shown in this study. the development of CMV hepatitis. Because the pathogenesis of CMV infection is thought to involve cell-mediated immune mechanisms. it is possible that this lower incidence of CMV infection is related to the immunosuppressive efficacy of FK506. Whatever the explanation. HLA-DR-matched liver transplants in FK506-treated patients are at increased risk for hepatitis caused by primary and secondary CMV infection. HLA·DR matching status seems germane in the consideration of CMV prophylaxis after liver transplantation.
Although structural similarities have been reported between CMV and HLA gene sequences (27) (28) (29) , the most likely explanation for the increased incidence of CMV hepatitis in HLA-DR-matched transplanted livers is the phenomenon of MHC restriction of antigen-specific lymphocyte reactivity. CMV infection of a transplanted liver leads to the expression of CMVderived antigens-which, in context with MHC molecules on the cell surface. are presented by infected cells recognized bv recipient T lymphocytes. Both class 1(5,6) and class II (8-11-) HLA-restricted CMV -specific T cell responses have been reported. HLA matching will permit MHC-restricted antigen This study has also shown a higher incidence of chronic rejection in liver transplant recipients who experienced CMV hepatitis. O'Grady et al. (20) have reported an association between CMV infection and the vanishing bile duct syndrome in liver transplant patients, and that HLA-DR matching of the liver donor represented an additional risk factor. These investigators concluded that HLA-DR status is not a predisposing factor for CMV infection. Our data suggest, instead, that HLA-DR matching increases the risk of CMV hepatitis. which then leads to a higher incidence of chronic rejection.
We have found that HLA-DR matching is associated with an earlier onset, but not a higher frequency, of chronic rejection_ Since this HLA-DR matching effect was also seen in patients without C':\1V hepatitis, it seems that additional HLA-DRrestricten l~'mphoc:-;te responses to as-yet-undefined antigens rna\' contrihute to accelerated chronic rejection of the li\'er allograft. Donald~on et al. ' 2) haVl' proposed a mechanism of HLA-DR-restricted T cell response to class I HLA antIgens to explain the higher risk of vanishing bile duct syndrome. This mechanism requires the generation of peptides from endogenous class I HLA molecules that would be presented by class II HLA molecules on the surface of the bile duct epithelium of the donor li\"t>r. At present. we are unaware of experimental suppOrt ll/ t hIS model. :YloreoVl'r. class I HLA antigens are readil~' secreted 11\' the transplanted liver (31) , and it seems pOSSIble that sllch soluble antigens are taken up and processed primarily h~' am igen-presenting cells of the recipient. Therefore. we believe t hat the accelerated chronic rejection of an HLA-DR-matched liver transplant is more likely related to HLA-DR-restricted immune responses during viral infection. and perhaps even autoimmune disease.
In summary. the findings descrihed in this report expand the concept of the dualistic role of HLA in liver transplantation and help explain why survival is poorer with better matches. Although HLA-DR matching reduces acute cellular rejection, it is apparent that HLA-DR matching will not only increase the risk of CM\' hepatitis but also accelerate chronic rejection. A better understanding of the different HLA-associated immune mechanisms within the liver allograft may lead to improved management strategies in hepatic transplantation.
Cerebral edema is the leading cause of death in patients with fulminant hepatic failure (FHF). Emergency OLT is often a life-saving therapy for FHF but severe cerebral edema is a contraindication to transplantation. We attempted to identify clinical and biochemical factors associated with the development of severe intracranial hypertension in FHF. Fever, psychomotor agitation, and arterial hypertension were more frequently observed preceding episodes of severe intracranial hypertension, and more than 50% of FHF patients with uncontrolled intracranial hypertension sustained severe brain injury in our series. These observations suggest that vigorous treatment of fever, arterial hypertension, and agitation are important aspects of the intensive care
